Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 628

1.

MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells.

Rajabi H, Hiraki M, Kufe D.

Oncogene. 2018 Jan 30. doi: 10.1038/s41388-017-0096-9. [Epub ahead of print] Review.

PMID:
29379165
2.

MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.

Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, Bouillez A, Hu X, Suzuki Y, Miyo M, Hata T, Hinohara K, Kufe D.

Cancer Res. 2018 Jan 1;78(1):205-215. doi: 10.1158/0008-5472.CAN-17-1636. Epub 2017 Dec 20.

PMID:
29263152
3.

CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice.

Sakakibara K, Sato T, Kufe DW, VonHoff DD, Kawabe T.

Oncotarget. 2017 Sep 16;8(45):78277-78288. doi: 10.18632/oncotarget.20968. eCollection 2017 Oct 3.

4.

CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding.

Saito N, Mine N, Kufe DW, Von Hoff DD, Kawabe T.

Oncotarget. 2017 Jun 22;8(43):74006-74018. doi: 10.18632/oncotarget.18598. eCollection 2017 Sep 26.

5.

Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma.

Tagde A, Markert T, Rajabi H, Hiraki M, Alam M, Bouillez A, Avigan D, Anderson K, Kufe D.

Oncotarget. 2017 Aug 10;8(41):69237-69249. doi: 10.18632/oncotarget.20144. eCollection 2017 Sep 19.

6.

CBP501 suppresses macrophage induced cancer stem cell like features and metastases.

Mine N, Yamamoto S, Saito N, Sato T, Sakakibara K, Kufe DW, VonHoff DD, Kawabe T.

Oncotarget. 2017 Jul 17;8(38):64015-64031. doi: 10.18632/oncotarget.19292. eCollection 2017 Sep 8.

7.

MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.

Bouillez A, Adeegbe D, Jin C, Hu X, Tagde A, Alam M, Rajabi H, Wong KK, Kufe D.

Oncoimmunology. 2017 Jul 5;6(9):e1338998. doi: 10.1080/2162402X.2017.1338998. eCollection 2017.

PMID:
28932637
8.

MUC1-C activates EZH2 expression and function in human cancer cells.

Rajabi H, Hiraki M, Tagde A, Alam M, Bouillez A, Christensen CL, Samur M, Wong KK, Kufe D.

Sci Rep. 2017 Aug 7;7(1):7481. doi: 10.1038/s41598-017-07850-0.

9.

Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.

Jain S, Washington A, Leaf RK, Bhargava P, Clark RA, Kupper TS, Stroopinsky D, Pyzer A, Cole L, Nahas M, Apel A, Rosenblatt J, Arnason J, Kufe D, Avigan D.

Mol Cancer Ther. 2017 Oct;16(10):2304-2314. doi: 10.1158/1535-7163.MCT-17-0060. Epub 2017 Jul 20.

PMID:
28729399
10.

MUC1-C is a target in lenalidomide resistant multiple myeloma.

Yin L, Tagde A, Gali R, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D.

Br J Haematol. 2017 Sep;178(6):914-926. doi: 10.1111/bjh.14801. Epub 2017 Jun 23.

PMID:
28643330
11.

MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.

Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D.

Leukemia. 2017 Dec;31(12):2780-2790. doi: 10.1038/leu.2017.163. Epub 2017 May 30.

12.

Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system.

Shukla V, Dalela M, Vij M, Weichselbaum R, Kharbanda S, Ganguli M, Kufe D, Singh H.

Nanomedicine. 2017 Jul;13(5):1833-1839. doi: 10.1016/j.nano.2017.03.004. Epub 2017 Mar 23.

PMID:
28343015
13.

MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.

Rajabi H, Kufe D.

Biochim Biophys Acta. 2017 Aug;1868(1):117-122. doi: 10.1016/j.bbcan.2017.03.003. Epub 2017 Mar 14. Review.

PMID:
28302417
14.

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.

Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, Maeda T, Hu X, Adeegbe D, Kharbanda S, Wong KK, Kufe D.

Oncogene. 2017 Jul 13;36(28):4037-4046. doi: 10.1038/onc.2017.47. Epub 2017 Mar 13.

15.

Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.

Ahmad R, Alam M, Hasegawa M, Uchida Y, Al-Obaid O, Kharbanda S, Kufe D.

Mol Cancer. 2017 Feb 2;16(1):33. doi: 10.1186/s12943-017-0608-9.

16.

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.

Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant MP, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi PP, Kufe D, Rosenblatt J, Avigan D.

Blood. 2017 Mar 30;129(13):1791-1801. doi: 10.1182/blood-2016-07-730614. Epub 2017 Jan 26.

PMID:
28126925
17.

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D.

Br J Haematol. 2017 Mar;176(6):929-938. doi: 10.1111/bjh.14493. Epub 2017 Jan 20.

PMID:
28107546
18.

MUC1-C drives DNA methylation in cancer.

Rajabi H, Tagde A, Kufe D.

Aging (Albany NY). 2016 Dec 28;8(12):3155-3156. doi: 10.18632/aging.101153. No abstract available.

19.

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.

Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D.

Sci Transl Med. 2016 Dec 7;8(368):368ra171.

20.

MUC1-C activates BMI1 in human cancer cells.

Hiraki M, Maeda T, Bouillez A, Alam M, Tagde A, Hinohara K, Suzuki Y, Markert T, Miyo M, Komura K, Ahmad R, Rajabi H, Kufe D.

Oncogene. 2017 May 18;36(20):2791-2801. doi: 10.1038/onc.2016.439. Epub 2016 Nov 28.

21.

MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.

Tagde A, Rajabi H, Stroopinsky D, Gali R, Alam M, Bouillez A, Kharbanda S, Stone R, Avigan D, Kufe D.

Oncotarget. 2016 Jun 28;7(26):38974-38987. doi: 10.18632/oncotarget.9777.

22.

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.

Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, Dries R, Almonte C, Herter-Sprie GS, Santos A, Feeney NB, Paweletz CP, Kulkarni MM, Bass AJ, Rustgi AK, Yuan GC, Kufe DW, Jänne PA, Hammerman PS, Sholl LM, Hodi FS, Richards WG, Bueno R, English JM, Bittinger MA, Wong KK.

JCI Insight. 2016 Sep 8;1(14):e89014.

23.

MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway.

Alam M, Bouillez A, Tagde A, Ahmad R, Rajabi H, Maeda T, Hiraki M, Suzuki Y, Kufe D.

Mol Cancer Res. 2016 Dec;14(12):1266-1276. Epub 2016 Sep 22.

24.

MUC1 in hematological malignancies.

Stroopinsky D, Kufe D, Avigan D.

Leuk Lymphoma. 2016 Nov;57(11):2489-98. doi: 10.1080/10428194.2016.1195500. Epub 2016 Jun 27. Review.

25.

MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors.

Hiraki M, Suzuki Y, Alam M, Hinohara K, Hasegawa M, Jin C, Kharbanda S, Kufe D.

Sci Rep. 2016 May 24;6:26643. doi: 10.1038/srep26643.

26.

DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells.

Rajabi H, Tagde A, Alam M, Bouillez A, Pitroda S, Suzuki Y, Kufe D.

Oncogene. 2016 Dec 15;35(50):6439-6445. doi: 10.1038/onc.2016.180. Epub 2016 May 23.

27.

Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.

Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, Tagde A, Maeda T, Hiraki M, Sukhatme VP, Kufe D.

Oncotarget. 2016 Mar 15;7(11):11756-69. doi: 10.18632/oncotarget.7598.

28.

MUC1-C drives MYC in multiple myeloma.

Tagde A, Rajabi H, Bouillez A, Alam M, Gali R, Bailey S, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D.

Blood. 2016 May 26;127(21):2587-97. doi: 10.1182/blood-2015-07-659151. Epub 2016 Feb 23.

29.

Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.

Bouillez A, Rajabi H, Pitroda S, Jin C, Alam M, Kharbanda A, Tagde A, Wong KK, Kufe D.

Cancer Res. 2016 Mar 15;76(6):1538-48. doi: 10.1158/0008-5472.CAN-15-1804. Epub 2016 Feb 1.

30.

Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target.

Raina D, Agarwal P, Lee J, Bharti A, McKnight CJ, Sharma P, Kharbanda S, Kufe D.

PLoS One. 2015 Aug 12;10(8):e0135156. doi: 10.1371/journal.pone.0135156. eCollection 2015.

31.

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.

Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark RA, Kupper TS, Palmer K, Coll MD, Rajabi H, Pyzer A, Bar-Natan M, Luptakova K, Arnason J, Joyce R, Kufe D, Avigan D.

Blood. 2015 Jul 16;126(3):354-62. doi: 10.1182/blood-2015-02-628149. Epub 2015 Jun 5.

32.

Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation.

Hasegawa M, Sinha RK, Kumar M, Alam M, Yin L, Raina D, Kharbanda A, Panchamoorthy G, Gupta D, Singh H, Kharbanda S, Kufe D.

Clin Cancer Res. 2015 May 15;21(10):2338-47. doi: 10.1158/1078-0432.CCR-14-3000. Epub 2015 Feb 23.

33.

MUC1-C activates the TAK1 inflammatory pathway in colon cancer.

Takahashi H, Jin C, Rajabi H, Pitroda S, Alam M, Ahmad R, Raina D, Hasegawa M, Suzuki Y, Tagde A, Bronson RT, Weichselbaum R, Kufe D.

Oncogene. 2015 Oct 1;34(40):5187-97. doi: 10.1038/onc.2014.442. Epub 2015 Feb 9.

34.

MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC.

Alam M, Ahmad R, Rajabi H, Kufe D.

Mol Cancer Res. 2015 Mar;13(3):449-60. doi: 10.1158/1541-7786.MCR-14-0363. Epub 2014 Nov 3.

35.

CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway.

Saito N, Sakakibara K, Sato T, Friedman JM, Kufe DW, VonHoff DD, Kawabe T.

Mol Cancer Ther. 2014 Dec;13(12):3013-23. doi: 10.1158/1535-7163.MCT-14-0064. Epub 2014 Sep 24.

36.

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.

Kharbanda A, Rajabi H, Jin C, Alam M, Wong KK, Kufe D.

Oncotarget. 2014 Oct 15;5(19):8893-905.

37.

Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.

Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong KK, Kufe D.

Clin Cancer Res. 2014 Nov 1;20(21):5423-34. doi: 10.1158/1078-0432.CCR-13-3168. Epub 2014 Sep 4.

38.

Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro.

Mine N, Yamamoto S, Kufe DW, Von Hoff DD, Kawabe T.

Mol Cancer Ther. 2014 Sep;13(9):2215-25. doi: 10.1158/1535-7163.MCT-13-0808. Epub 2014 Jul 22.

39.

Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.

Alam M, Rajabi H, Ahmad R, Jin C, Kufe D.

Oncotarget. 2014 May 15;5(9):2622-34.

40.

Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9.

Kumar M, Gupta D, Singh G, Sharma S, Bhat M, Prashant CK, Dinda AK, Kharbanda S, Kufe D, Singh H.

Cancer Res. 2014 Jun 15;74(12):3271-81. doi: 10.1158/0008-5472.CAN-13-2015. Epub 2014 Apr 16.

41.

Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.

Yin L, Kufe T, Avigan D, Kufe D.

Blood. 2014 May 8;123(19):2997-3006. doi: 10.1182/blood-2013-11-539395. Epub 2014 Mar 14.

42.

MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells.

Liu S, Yin L, Stroopinsky D, Rajabi H, Puissant A, Stegmaier K, Avigan D, Kharbanda S, Kufe D, Stone R.

Blood. 2014 Jan 30;123(5):734-42. doi: 10.1182/blood-2013-04-493858. Epub 2013 Nov 26.

43.

MUC1-C oncoprotein activates ERK→C/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells.

Alam M, Ahmad R, Rajabi H, Kharbanda A, Kufe D.

J Biol Chem. 2013 Oct 25;288(43):30892-903. doi: 10.1074/jbc.M113.477158. Epub 2013 Sep 16.

44.

Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.

Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D.

Oncogene. 2014 Jun 26;33(26):3422-31. doi: 10.1038/onc.2013.308. Epub 2013 Aug 5.

45.

MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.

Stroopinsky D, Rosenblatt J, Ito K, Mills H, Yin L, Rajabi H, Vasir B, Kufe T, Luptakova K, Arnason J, Nardella C, Levine JD, Joyce RM, Galinsky I, Reiter Y, Stone RM, Pandolfi PP, Kufe D, Avigan D.

Cancer Res. 2013 Sep 1;73(17):5569-79. doi: 10.1158/0008-5472.CAN-13-0677. Epub 2013 Jul 18.

46.

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D.

Clin Cancer Res. 2013 Jul 1;19(13):3640-8. doi: 10.1158/1078-0432.CCR-13-0282. Epub 2013 May 17.

47.

MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.

Rajabi H, Alam M, Takahashi H, Kharbanda A, Guha M, Ahmad R, Kufe D.

Oncogene. 2014 Mar 27;33(13):1680-9. doi: 10.1038/onc.2013.114. Epub 2013 Apr 15.

48.

Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.

Kharbanda A, Rajabi H, Jin C, Raina D, Kufe D.

Mol Cancer Res. 2013 Jul;11(7):714-23. doi: 10.1158/1541-7786.MCR-12-0668. Epub 2013 Mar 28.

49.

Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.

Uchida Y, Raina D, Kharbanda S, Kufe D.

Cancer Biol Ther. 2013 Feb;14(2):127-34. doi: 10.4161/cbt.22634. Epub 2012 Oct 31.

50.

Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).

Vasir B, Zarwan C, Ahmad R, Crawford KD, Rajabi H, Matsuoka K, Rosenblatt J, Wu Z, Mills H, Kufe D, Avigan D.

J Immunother. 2012 Sep;35(7):555-69. doi: 10.1097/CJI.0b013e31826a73de.

Supplemental Content

Support Center